助仙丹与炔雌醇环丙孕酮对多囊卵巢综合征大鼠血清雄激素及卵巢形态的影响对比
|
摘要
目的比较助仙丹与炔雌醇环丙孕酮对多囊卵巢综合征大鼠血清雄激素及卵巢形态的影响。方法取32只大鼠随机分为空白对照组(8只)和实验组(24只),实验组大鼠采用左炔诺孕酮硅胶棒于皮下埋植及注射用人绒毛膜促性腺激素于皮下往射以构建多囊卵巢综合征实验模型,并将实验组随机分为A组(未应用任何用药)、B组(应用炔雌醇环丙孕酮)、C组(应用助仙丹),每组各8只。比较各组大鼠体重、卵巢质量、雄激素浓度及卵巢形态等差异。结果C组大鼠用药后体重较A组明显下降(P <0. 05),而与空白对照组、B组比较,并无显著差异(P> 0. 05)。C组大鼠卵巢质量较A组明显下降(P <0. 05),而与空白对照组、B组比较,并无显著差异(P> 0. 05); A组大鼠卵巢质量较空白对照组明显增高(P <0. 05)。各组大鼠雄激素浓度的比较,差异无统计学意义(P> 0. 05)。C组大鼠卵巢组织中存在一定数量的闭锁卵泡,出现一定数量的白体和黄体且正常成熟卵泡,颗粒细胞层明显多于A、B组,且与空白对照组的颗粒层数接近,但排列不一。结论相比炔雌醇环丙孕酮,助仙丹更能够改善多囊卵巢综合征大鼠卵巢形态,有助于促进大鼠正常排卵。
Objective To compare the effects of zhuxiandan and ethinylestradiol cycloproterone on serum androgen and ovarian morphological in rats with polycystic ovary syndrome. Methods 32 rats were randomly divided into blank control group( 8 rats) and experimental group( 24 rats). Rats in experimental group were subcutaneously implanted with levonorgestrel silica gel rod and injected with human chorionic gonadotropin for injection to establish the experimental model. The experimental group was randomly divided into group A( without any medication) and group B( ethynestradiol cycloprogesterone),group C( Zhuxiandan),with 8 rats in each group. The differences of body weight,ovarian mass,androgen concentration and ovarian morphology were compared among the groups. Results The body weight of group C was significantly lower than that of group A( P < 0. 05),but there was no significant difference compared with the blank control group and group B( P > 0. 05). The ovarian quality of group C was significantly lower than that of group A( P < 0. 05),but there was no significant difference compared with the blank control group and group B( P > 0. 05). The ovarian quality of group A was significantly higher than that of the blank control group( P < 0. 05). There was no significant difference in the concentration of androgen between groups( P > 0. 05). There were a certain number of atresia follicles in the ovarian tissues of rats in group C,a certain number of white bodies and corpus luteum,and normal mature follicles. The granulosa cell layer in group C was significantly more than that in group A and B,and was similar to that in the blank control group,but the arrangement was different. Conclusion Compared with ethinylestradiol cycloprogesterone,Zhuxiandan can improve the ovarian morphology of rats with polycystic ovary syndrome and promote normal ovulation in rats.
Objective To compare the effects of zhuxiandan and ethinylestradiol cycloproterone on serum androgen and ovarian morphological in rats with polycystic ovary syndrome. Methods 32 rats were randomly divided into blank control group( 8 rats) and experimental group( 24 rats). Rats in experimental group were subcutaneously implanted with levonorgestrel silica gel rod and injected with human chorionic gonadotropin for injection to establish the experimental model. The experimental group was randomly divided into group A( without any medication) and group B( ethynestradiol cycloprogesterone),group C( Zhuxiandan),with 8 rats in each group. The differences of body weight,ovarian mass,androgen concentration and ovarian morphology were compared among the groups. Results The body weight of group C was significantly lower than that of group A( P < 0. 05),but there was no significant difference compared with the blank control group and group B( P > 0. 05). The ovarian quality of group C was significantly lower than that of group A( P < 0. 05),but there was no significant difference compared with the blank control group and group B( P > 0. 05). The ovarian quality of group A was significantly higher than that of the blank control group( P < 0. 05). There was no significant difference in the concentration of androgen between groups( P > 0. 05). There were a certain number of atresia follicles in the ovarian tissues of rats in group C,a certain number of white bodies and corpus luteum,and normal mature follicles. The granulosa cell layer in group C was significantly more than that in group A and B,and was similar to that in the blank control group,but the arrangement was different. Conclusion Compared with ethinylestradiol cycloprogesterone,Zhuxiandan can improve the ovarian morphology of rats with polycystic ovary syndrome and promote normal ovulation in rats.
引文
[1] Macut D,Bjeki!c-Macut J,Raheli!c D,et al. Insulin and the polycystic ovary syndrome[J]. Diabetes Res Clin Pract,2017,130(1):163-170.
[2] Behboudi-Gandevani S,Ramezani Tehrani F,Hosseinpanah F,et al. Cardiometabolic risks in polycystic ovary syndrome:long-term populationbased follow-up study[J]. Fertil Steril,2018,110(7):1377-1386.
[3] Fisch SC,Nikou AF,Wright EA,et al. Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome[J]. Fertil Steril,2018,110(7):1367-1376.
[4] Lua ACY,How CH,King TFJ. Managing polycystic ovary syndrome in primary care[J]. Singapore Med J,2018,59(11):567-571.
[5] Le MT,Nguyen VQH,Truong QV,et al. Metabolic syndrome and insulin resistance syndrome among infertile women with polycystic ovary syndrome:A cross-sectional study from central Vietnam[J]. Endocrinol Metab(Seoul),2018,33(4):447-458.
[6] Teede HJ,Misso ML,Boyle JA,et al. Translation and implementation of the Australian-led PCOS guideline:clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome[J]. Med J Aust,2018,209(7):S3-S8.
[7]马丽亚,李宾玲,张大伟,等.《傅青主女科》从肾论治不孕症探析[J].中医学报,2015,30(12):1801-1803.
[8] Pluta D,Franik G,Blukacz,et al. The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome[J].Eur Rev Med Pharmacol Sci,2018,22(21):7379-7384.
[9]辛俊,郭慧梅,谭同焕,等.自拟中药排卵汤联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床效果研究[J].临床和实验医学杂志,2017,16(3):293-295.
[2] Behboudi-Gandevani S,Ramezani Tehrani F,Hosseinpanah F,et al. Cardiometabolic risks in polycystic ovary syndrome:long-term populationbased follow-up study[J]. Fertil Steril,2018,110(7):1377-1386.
[3] Fisch SC,Nikou AF,Wright EA,et al. Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome[J]. Fertil Steril,2018,110(7):1367-1376.
[4] Lua ACY,How CH,King TFJ. Managing polycystic ovary syndrome in primary care[J]. Singapore Med J,2018,59(11):567-571.
[5] Le MT,Nguyen VQH,Truong QV,et al. Metabolic syndrome and insulin resistance syndrome among infertile women with polycystic ovary syndrome:A cross-sectional study from central Vietnam[J]. Endocrinol Metab(Seoul),2018,33(4):447-458.
[6] Teede HJ,Misso ML,Boyle JA,et al. Translation and implementation of the Australian-led PCOS guideline:clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome[J]. Med J Aust,2018,209(7):S3-S8.
[7]马丽亚,李宾玲,张大伟,等.《傅青主女科》从肾论治不孕症探析[J].中医学报,2015,30(12):1801-1803.
[8] Pluta D,Franik G,Blukacz,et al. The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome[J].Eur Rev Med Pharmacol Sci,2018,22(21):7379-7384.
[9]辛俊,郭慧梅,谭同焕,等.自拟中药排卵汤联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床效果研究[J].临床和实验医学杂志,2017,16(3):293-295.